A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR

被引:25
|
作者
Wang, Chunsheng [1 ]
Zhao, Kewei [1 ,2 ]
Hu, Shanliang [1 ]
Huang, Yong [3 ]
Ma, Li [3 ]
Song, Yipeng [1 ]
Li, Minghuan [2 ]
机构
[1] Qingdao Univ, Coll Med, Affiliated Yantai Yuhuangding Hosp, Dept Radiat Oncol, 20 Yudong Rd, Yantai 264000, Shandong, Peoples R China
[2] Shandong Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China
[3] Shandong Univ, Shandong Canc Hosp & Inst, Dept Nucl Med, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China
关键词
Esophageal squamous cell carcinoma; Predictive model; Treatment response; Concurrent chemoradiotherapy; SUVmean; NLR; METABOLIC TUMOR VOLUME; LYMPHOCYTE RATIO; NEUTROPHIL/LYMPHOCYTE RATIO; HEMATOLOGICAL PARAMETERS; PATHOLOGICAL RESPONSE; PROGNOSTIC VALUE; LUNG-CANCER; FDG UPTAKE; PET/CT; NEUTROPHIL;
D O I
10.1186/s12885-020-07040-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We conducted this study to combine the mean standardized uptake value (SUVmean) and neutrophil to lymphocyte ratio (NLR) to establish a strong predictive model for patients with esophageal squamous cell carcinoma (ESCC) after concurrent chemoradiotherapy (CCRT). Methods We retrospectively analyzed 163 newly diagnosed ESCC patients treated with CCRT. Eighty patients (training set) were randomly selected to generate cut-off SUVmean and NLR values by receiver operating characteristic (ROC) curve analysis and to establish a predictive model by using the independent predictors of treatment outcomes. Then, we evaluated the performance of the prediction model regarding treatment outcomes in the testing set (n = 83) and in all sets. Results A high SUVmean (> 5.81) and high NLR (> 2.42) at diagnosis were associated with unfavorable treatment outcomes in patients with ESCC. The prediction model had a better performance than the simple parameters (p < 0.05). With a cut-off value of 0.77, the prediction model significantly improved the specificity and positive predictive value for treatment response (88.9 and 92.1% in the training set, 95.8 and 97.1% in the testing set, and 92.2 and 91.8% in all sets, respectively). Conclusions The pretreatment SUVmean and NLR were independent predictors of treatment response in ESCC patients treated with CCRT. The predictive model was constructed based on these two parameters and provides a highly accurate tool for predicting patient outcomes.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma
    Habu, Takumi
    Kumanishi, Ryosuke
    Ogata, Takatsugu
    Fujisawa, Takeshi
    Mishima, Saori
    Kotani, Daisuke
    Kadowaki, Shigenori
    Nakamura, Masaki
    Hojo, Hidehiro
    Fujiwara, Hisashi
    Kumagai, Shogo
    Koyama, Shohei
    Fujita, Takeo
    Kinoshita, Takahiro
    Nishikawa, Hiroyoshi
    Yano, Tomonori
    Tajika, Masahiro
    Muro, Kei
    Mitsunaga, Shuichi
    Kojima, Takashi
    Bando, Hideaki
    ESOPHAGUS, 2023, 20 (03) : 533 - 540
  • [22] Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma
    Takumi Habu
    Ryosuke Kumanishi
    Takatsugu Ogata
    Takeshi Fujisawa
    Saori Mishima
    Daisuke Kotani
    Shigenori Kadowaki
    Masaki Nakamura
    Hidehiro Hojo
    Hisashi Fujiwara
    Shogo Kumagai
    Shohei Koyama
    Takeo Fujita
    Takahiro Kinoshita
    Hiroyoshi Nishikawa
    Tomonori Yano
    Masahiro Tajika
    Kei Muro
    Shuichi Mitsunaga
    Takashi Kojima
    Hideaki Bando
    Esophagus, 2023, 20 : 533 - 540
  • [23] Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma
    Pond, Gregory R.
    Milowsky, Matthew I.
    Kolinsky, Michael P.
    Eigl, Bernhard J.
    Necchi, Andrea
    Harshman, Lauren C.
    Di Lorenzo, Giuseppe
    Dorff, Tanya B.
    Lee, Richard J.
    Sonpavde, Guru
    CLINICAL GENITOURINARY CANCER, 2014, 12 (06) : 440 - 446
  • [24] Primary concurrent chemoradiotherapy for locally advanced laryngeal squamous cell carcinoma
    Adjogatse, D.
    De Felice, F.
    Suh, Y.
    Jeannon, J.
    Oakley, R.
    Simo, R.
    Lei, M.
    Urbano, T. Guerrero
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S653 - S653
  • [25] Endoscopic traversability in patients with locally advanced esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy: Is it an important prognostic factor?
    Hyung, Kang Sun
    Kyu, Sung Jae
    Yong, Jeong Hyun
    Seok, Moon Hee
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Endoscopic Traversability in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy: Is it an Important Prognostic Factor?
    Moon, Hee Seok
    Jeong, Hyun Yong
    Sung, Jaekyu
    GASTROINTESTINAL ENDOSCOPY, 2017, 85 (05) : AB212 - AB212
  • [27] Development and Validation of a Nomogram for Predicting Overall Survival to Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
    Wang, Chenyu
    Cheng, Xinyu
    Jin, Linzhi
    Ren, Runchuan
    Wang, Shaohua
    Zheng, Anping
    Hao, Anlin
    Zhou, Fuyou
    Zhang, Yaowen
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [28] A prospective study of apatinib in combination with neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
    Wang, J.
    He, M.
    Yao, J.
    Cheng, Y.
    Wu, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S931 - S931
  • [29] Induction chemotherapy followed by concurrent chemoradiotherapy with/without esophagectomy for locally advanced esophageal squamous cell carcinoma
    Lin, C.
    Hsu, C.
    Cheng, J. C.
    Lee, J.
    Tsai, Y.
    Luo, J.
    Hsu, F.
    Wang, H.
    Lee, Y.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Nimotuzumab in combination with preoperative concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A prospective trial
    Wu, Xiaoyuan
    Chen, Yongshun
    Yang, Yuanyuan
    Hao, Daxuan
    Li, Xue
    He, Chunyu
    Liu, Jinsong
    Wang, Jianhua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)